TX-MAVENIR
8.4.2020 03:02:04 CEST | Business Wire | Press release
Mavenir, the industry's only end-to-end cloud-native network software provider for Communications Service Providers, announced that it has successfully deployed its next-generation voice and messaging solution as part of Rakuten Mobile’s communication app, Rakuten Link.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005050/en/
Rakuten Link is a communication platform based on the GSMA RCS (Rich Communication Services) standards. Unlike other OTT (Over the Top) messaging apps where communication is limited to between app users, Rakuten Link allows users to make domestic and international calls to other mobile phones and fixed lines, sending and receiving SMS messages in Japan and overseas, in addition to supporting basic communication features such as group chat, sending and receiving photos, videos and files. All these communications are possible while being connected to Wi-Fi or cellular networks.
The deployment includes Mavenir’s 5G-ready platform that monetizes voice and messaging for domestic and international roaming at low costs, integration of Rakuten ID single sign-on, and is completely cloud-based with full NFV (Network Functions Virtualization) deployed on the Rakuten Mobile platform. The platform is also ready for advanced services such as video calling, voice and video conferencing, and multiple devices including desktop applications.
“Rakuten Mobile’s unique cloud-based network architecture allows flexible deployment of new services such as Rakuten Link. Partnering with Mavenir on the deployment of next-generation voice and messaging services is a key milestone,” said Tareq Amin, Representative Director, Executive Vice President and CTO of Rakuten Mobile. “Driving disruptive innovation like this in the telecommunications sector will position us to provide our subscribers in Japan with flexible, stable and competitive services.”
“As a leading network software provider with our virtualized, cloud-based RCS solution enabled us to help Rakuten Mobile quickly and easily provide voice and messaging infrastructure forming part of their network launch this year,” said Pardeep Kohli, President, and CEO of Mavenir. “Mavenir’s fully virtualized RCS application server and application client will enable Rakuten Mobile to launch new innovative services quickly for enterprises and subscribers.”
By utilizing Mavenir’s RCS solution, Rakuten Mobile provides its subscribers with next-generation rich messaging services based on evolving GSMA Universal Profile (UP) RCS standards. Services include session-based messaging to RCS capable clients, allowing subscribers to instant message (IM), group chat and file share, and supports multi-device scenarios based on RCS standards that support voice and video QoS.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc. Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom